Conditions: Benign Prostatic Hypertrophy
Keywords: Cetrorelix BPH
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 528
Healthy volunteers: no

Brief summary:
Benign Prostatic Hyperplasia (BPH) is the most common hyperplastic disease occuring in human males over the age of 50 which increases in prevalence with age and 40% of males reported moderate or severe urinary symptoms of prostatism by the age of 50 to 80. The purpose of this study is to collect safety and efficacy data for this dosage regimen of cetrorelix pamoate.

For this study, study medication (Cetrorelix pamoate) is administered by injection in the buttocks (Intramuscular).

Detailed description:

Arms:
arm 1: Drug: Cetrorelix 52 mg week 0, and 26 mg week 2, intra muscular-2 doses in 2 weeks and follow up to week 26.

Interventions: intervention 1: Cetrorelix Pamoate
Intervention descriptions: intervention 1: Cetrorelix Pamoate IM, 52 mg week 0, 26 mg week 2,

Protocol document: